| Document |
Document Title |
|
WO/1992/004364A1 |
A method of linking nucleosides with a siloxane bridge comprising reacting a 3'-silylated-5'-protected nucleoside with an unprotected nucleoside is disclosed. The silylated and unprotected nucleosides may be either monomeric nucleosides ...
|
|
WO/1992/003577A1 |
Novel oligonucleotides formed from alpha-D-arabinofuranosyl nucleoside monomers, including oligonucleotides in which one or more of the monomer units is functionalized, are disclosed herein, as well as functionalized monomeric alpha-D-ar...
|
|
WO/1992/003568A1 |
Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are p...
|
|
WO/1992/002528A1 |
Novel reagents useful in a variety of biochemical and chemical contexts, including nucleic hybridization assays and chemical phosphorylation of hydroxyl-containing compounds. The reagents are particularly useful for introducing cleavable...
|
|
WO/1992/001699A1 |
Platinum complexes are disclosed which contain at least one leaving group and at least one detectable group. These complexes can be used for diagnostic purpose and for the labelling of nucleic acids. Specific example is Pt(ethylenediamin...
|
|
WO/1992/001700A1 |
The instant invention is drawn to 2'-fluoroarabinofuranosyl compounds and a process for preparing same.
|
|
WO/1991/019730A1 |
The selected sequence-directed hydrolysis of RNA under physiologically relevant conditions is described using conjugates comprising metal complexes covalently linked to oligodeoxynucleotides as hydrolysis agents. The oligodeoxynucleotide...
|
|
WO/1991/019713A1 |
A novel pyrimidine nucleoside derivative of formula (1) or (2) and a salt thereof, wherein R1 represents amino which may be substituted with hydroxy or acyl; R2 represents hydrogen or C1 to C4 alkyl; R3 represents hydrogen or hydroxy; an...
|
|
WO/1991/017755A1 |
Methods for achieving therapeutic treatment of diseases and for regulating gene expression in biological experimental systems via modification or removal of the 5' Cap structure of targeted ribonucleic acids are disclosed. Modification o...
|
|
WO/1991/018007A1 |
Fluorescent dyes which are free of aggregation and serum binding are provided. These dyes are suitable for applications such as fluorescence immunoassays, in vivo imaging and in vivo tumor therapy.
|
|
WO/1991/018006A1 |
Marker components are provided which are compatible with aqueous solutions, exhibit favorable fluorescence properties and exhibit decreased non-specific binding to macromolecules in solution. These marker components are useful in applica...
|
|
WO/1991/016333A1 |
2',3'-dideoxy-4'-thioribonucleosides useful as antiviral agents in the treatment and prevention of AIDS are disclosed. In accordance with one aspect of the invention there are provided compounds of formula (I), where X = H, N�3? or F, ...
|
|
WO/1991/013900A1 |
A novel process is provided for producing a nucleoside, such as cytarabine, or a nucleoside analogue, comprising the step of reacting 2,2'-O-cyclonucleoside or an analogue thereof with an amine. Preferably, the process is conducted in th...
|
|
WO/1991/013901A1 |
Compounds of formula (IV), wherein R?6� is selected from the group comprising a trifluoromethyl group, a C�1?-C�6? alkyl group and a C�6?-C�9? aryl group, and R?1� is selected from the group comprising hydrogen, trityl, metho...
|
|
WO/1991/010671A1 |
Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alt...
|
|
WO/1991/009048A1 |
A novel class of pharmaceutically active boronated nucleosides are provided. The nucleosides are boronated at a ring nitrogen of the purine or pyrimidine or analogues thereof. Also provided are phosphate esters of these nucleosides and o...
|
|
WO/1991/008213A1 |
Disclosed are oligonucleoside boranophosphates, or salts thereof, comprising a chain of natural or modified ribonucleotides or deoxyribonucleotides, containing at least one boronated internucleotide phospodiester linkage of formula (III)...
|
|
WO/1991/006555A1 |
Nucleoside derivatives having a potent antiprotozoan activity and a reduced adverse effect and being effective in treating diseases caused by protozoan, such as 2'- and/or 5'-acylated, aralkylated or silylated 3'-deoxyinosine; allopurino...
|
|
WO/1990/014825A1 |
A specific inhibitor product ofr retrovirus reverse transcriptase consists of an organic thio-compound with at least one S-Au link. Said compound may be a thio-glucose, such as 1-beta-D-aurothioglucose, and 2,3,4,6-tetra-O-acetyl-1-thio-...
|
|
WO/1990/010014A1 |
A vitamin B12 derivative of formula (I) and salts thereof, wherein L represents a ligand bound to the cobalt atom of the corrin ring, B represents a base having a heterocyclic structure, and R represents an (un)substituted hydrocarbon gr...
|
|
WO/1990/008157A1 |
Platinum compounds useful in the treatment of cancer are disclosed. Compositions containing these compounds and methods of using the same are also discussed. Compounds having formula (I) wherein n is 0 or 1 and when n is 1, R¿1? is H or...
|
|
WO/1990/005732A1 |
This invention concerns a coordination complex or salt thereof which is spectroscopically or photoactively determinable when bound to DNA having formula (I), wherein M is a suitable transition metal and each of R1, R2 and R3 is ehtylened...
|
|
WO/1990/002133A1 |
An improved chemical process for preparing the anti-ulcer medication, sucralfate, and a sucralfate-like product. Sucrose is reacted with chlorosulfonic acid in pyridine or picoline. The ammonium salt is then formed and reacted with alumi...
|
|
WO/1990/001488A1 |
Compounds of general formula (I), wherein R1 is alkyl; alkenyl; alkynyl; tri(alkyl)silylethyl; optionally substituted aryl; mono- or di-halogenalkyl; phenylalkyl; a group of formula (II): R3-(CH2)n-S(O)m-CH2CH2- or formula (IIa): (R3-(CH...
|
|
WO/1990/000884A1 |
Organic silicon compounds such as tetraloweralkylorthosilicates, silicon tetracarboxylates, and silicon-containing reaction products derived from carbohydrates, such as glucose, sucrose, and ascorbic acid are useful in treating, preventi...
|
|
WO/1990/000557A1 |
5-Substituted uridine derivative represented by general formula (I) [wherein X represents F or CF3, R1 and R2 each represents -OSi-(R4)(R5)(R6) (wherein R4, R5 and R6 each represents a C1 to C10 alkyl group or the like), OH, an aminoacyl...
|
|
WO/1989/012380A2 |
Synthetic analogs of 2',5'-oligoadenylate wherein the aglycon, ribosyl moiety and/or terminal nucleoside have been modified are effective therapeutic agents, particularly against HIV infection. The analogs are utilized in compositions an...
|
|
WO/1989/012640A1 |
A ligated technetium (III/II) complex is useful as a brain perfusion imaging agent. The complex has a technetium (III/II) center surrounded by six ligating moieties. The complex preferably has a reduction potential Tc(III) to Tc(II) whic...
|
|
WO/1989/011861A1 |
Derivatives of platinum (P) with polyanion of deoxyribonucleic acid have the following general formula (I): {[PtCl(NH3)]6(OH)x(H2O)y}n where DNA-m = ( C39H55-rO32N15P4 )n-m; n = 2000U200; when x = 0, y = 12, m = 6n, r = 6; when x = 2, y ...
|
|
WO/1989/009054A1 |
It has been surprisingly found that gold compounds may be applied in topical preparations as an effective treatment of local or systemic inflammatory conditions and/or as antibacterial agents. The present invention therefore relates to n...
|
|
WO/1989/005815A1 |
Bis-platinum complexes of formula (I), wherein A is a disubstituted 1,4-anthracenedione; X, X' are ligands selected from the group consisting of Cl, Br, OH, CH3SOCH3.OH or CH3SOCH3.Hal or, taken together, form the anion of a dicarboxylic...
|
|
WO/1989/000575A1 |
Compounds of formula (I), wherein each of R1 and R2 is independently selected from the group consisting of halogen, hydroxy, or mono carboxylic acid or R1 and R2 together is a multifunctional carboxylic acid residue which forms a ring wi...
|
|
WO/1989/000574A1 |
Platinum compounds useful in the treatment of cancer are disclosed. Compositions containing these compounds and methods of using the same are also discussed. Platinum compounds of formula (I) and (II) and (III) are disclosed. Composition...
|
|
WO/1988/010264A1 |
A nucleoside derivative of formula (I), characterized in that: Y is H or OH or a protected hydroxy group; X is H, a phosphonate group or a phosphoramidite group of formula (II), where R1 and R2 are the same or different, and are selected...
|
|
WO/1988/003925A1 |
A water-soluble square-planar cis-platinum(II) four-coordinate complex having the formula: trans-R,R-DACH Pt(II) X2 or trans-R,R-DACH Pt(II) Y, wherein X is a monovalent cation, two of which are present, selected from the group consistin...
|
|
WO/1987/002708A1 |
Nucleic acid probes which are chemically tagged with moieties which chelate the trivalent lanthanides Eu+3, Tb+3 and Sm+3. Also provided are methods of making said probes and methods of using the probes in hybridization assays. The probe...
|
|
WO/1987/002365A2 |
A high yielding process for converting 3,2',6'-tri-N-acetyl sisomicin to netilmicin comprising the step of silylating the starting material at the 5,2'' positions, and optionally at the 4'' position, converting the 1-amino substituents t...
|
|
WO/1986/004244A1 |
A coordination complex and salts and optically resolved enantiomers thereof, of the formula (R)3---M, wherein R comprises 1,10-phenanthroline or a substituted derivative thereof, M comprises a suitable transition metal, e.g. ruthenium(II...
|
|
WO/1985/000747A1 |
The toxic effects of gold compounds used in the treatment of rheumatoid arthritis can be negated by the use of a selenium-containing compound. A new selenium-containing gold compound has been found to be useful as a gold compound type an...
|
|
WO/1979/001088A1 |
New glucosamin silyl compounds of formula: (FORMULA) wherein X is a carbonyl group, R1, R4 and R6 a tri-alkyl-lower-sylil group, in particular trimethyl-silyl, R2 is an alkyl group eventually substituted or an aryl carbocylic group, R3 i...
|
|
JP7452549B2 |
The present invention has an object to provide a phosphoramidite activator that improves a solubility of 5-benzylthio-1H-tetrazolein acetonitrile and does not reduce the yield and a purity of a target product.The present invention relate...
|
|
JP2024508991A |
A composition containing a silylated polysaccharide, wherein the silylated polysaccharide (a) has linked fructose, galactose, anhydrogalactose, or glucose monosaccharide units (provided that the glycosidic linkage of glucose is α and (b...
|
|
JP7436151B2 |
To provide a vitamin B12 photostabilizing method by which the decomposition of the vitamin B12 due to light exposure is suppressed.A composition containing a vitamin B12 is blended with a vitamin E, so that the decomposition of the vitam...
|
|
JP7371829B2 |
A polymerizable compound represented by the following Formula E-1 or Formula E-4:The polymerizable compound according to the present disclosure is allows stereoselective synthesis of a boranophosphate oligomer, regardless of whether a ba...
|
|
JP2023113730A |
To provide methods for preparing and purifying phosphoramidite for oligonucleotide synthesis.The method comprises the following steps a) to c): a) removing water from a purification medium; b) contacting the purification medium with a ph...
|
|
JP2023109826A |
To provide compounds that can be used as adjuvants for prophylactic and therapeutic vaccines for infectious diseases and cancer, and provide therapeutic methods that use the compounds as immunotherapeutics for cancer, infectious diseases...
|
|
JP7286320B2 |
The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.
|
|
JP2023516965A |
The present disclosure provides a class of conjugates of general formula (X), a class of TLR9 agonist derivatives such as formulas (I), (XX) and (XXI), STING, as defined herein. Certain diastereomers of agonists, a class of STING agonist...
|
|
JP7254374B2 |
This invention relates to modifications of β-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response.
|
|
JP7173467B2 |
To provide a nucleoside that is more practical for RNA pharmaceuticals and other applications and use thereof. A nucleoside derivative represented by formula (1) or (2) below, or a salt thereof.(In formula (1), R1represents a hydrogen at...
|
